Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-01
2005-11-01
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S184000
Reexamination Certificate
active
06960583
ABSTRACT:
The present invention relates to pyrazolotriazines according to formula (I)and stereoisomers, isomers and salts thereof wherein R1-R5are selected from certain alkyl, aryl and heteroaryl species as defined in the specification wherein all of the compounds are useful as CRF antagonists and are thus useful in the treatment of neurological disorders as well as a multitude of other CRF associated diseases or conditions.
REFERENCES:
patent: 3910907 (1975-10-01), O'Brien, et al.
patent: 3920652 (1975-11-01), Springer et al.
patent: 3995039 (1976-11-01), Rooney et al.
patent: 4021556 (1977-05-01), Springer et al.
patent: 4567263 (1986-01-01), Eicken et al.
patent: 4621556 (1986-11-01), Soltysiak et al.
patent: 4892576 (1990-01-01), Kruger et al.
patent: 4997940 (1991-03-01), Vinogradoff et al.
patent: 5137887 (1992-08-01), Hashimoto et al.
patent: 5397774 (1995-03-01), Nugent et al.
patent: 5484760 (1996-01-01), Bussler et al.
patent: 6060478 (2000-05-01), Gilligan et al.
patent: 6124289 (2000-09-01), He et al.
patent: 6136809 (2000-10-01), Gilligan et al.
patent: 6191131 (2001-02-01), He et al.
patent: 6194410 (2001-02-01), Bos et al.
patent: 4 243 279 (1994-06-01), None
patent: 0 374 448 (1990-06-01), None
patent: 0 511 528 (1994-02-01), None
patent: 0 549 149 (1994-04-01), None
patent: 0 594 149 (1994-04-01), None
patent: 0 662 477 (1995-07-01), None
patent: 0 269 859 (1995-10-01), None
patent: 0 714 898 (1996-06-01), None
patent: 0 521 622 (1997-08-01), None
patent: 0 591 528 (1998-12-01), None
patent: 0 531 901 (2003-03-01), None
patent: WO 92/10098 (1992-06-01), None
patent: WO 94/09017 (1994-04-01), None
patent: WO 95/10506 (1995-04-01), None
patent: WO 95/35298 (1995-12-01), None
patent: WO 97/29109 (1997-08-01), None
patent: WO 98/03510 (1998-01-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 99/38868 (1999-08-01), None
Gray et al. Journal of chemical society, Perkins transactions I: Organic and Bio-Organic Chemistry 8, 885-888, 1978.
Mitchell, Neurosci. Biobehav. Rev. 22(5); 635-651, 1998.
Deeb, A., et .al, “Preparation of naphtha[2,1-e]pyrazolo[5,1-c][1,2,4]triazine, dipyrazolo[5,1-c:3',4'-e][1,2,4]triazines and pyrazolo-[1,5-c][1,2,4]triazine derivatives,”Collect. Czech. Chem. Commun,1990, 55, 2790-2794.
Ege, G., et al. “Reactions with diazoazoles. Part IV. (1). [7+2]-and [11+2]-cyclocondensation reactions of diazoazoles with acyltriphenylphosphonium methylides to azolo[5,1cII1,2,4]triazines,”J. Heterocyclic Chemistry,Jun. 1981, 18(4), 675-677.
Gray, E.J., et al., “Triazines and related products. Part 21. Cyclisation of 3-amino-5-hydrazinopyrazole and 3-amino-5-hydrazino-1,2,4-triazole to azolo-[5,1-c][1,2,4]triazines,”J. Chemical Society,1978, 885-888.
Ibrahim, et al.,Arch. Pharm.(Weinheim), 1987, 320, 487-491.
Journal of Med. Chem.,1981, 24, 610-613.
Joshi, et al.,J. Prakt. Chemie,1979, 321(2), 341-344.
Kandeel, E.M., et al., “Reactions with heterocyclic amidines . . . ,”Chemical Astracts Service, Columbus, OH,Accession No. 99:122411, RN87031-23-0 & Arch. Pharm. (Weinheim, Ger.), 1983, 316(8), 713-718.
Maquestiau, et al.,Bull. Soc. Belg.,1992, 101(2), 131-136.
Ramiz, M.M.M., et al., “Studies on amino-azoles; synthesis of . . . ,”Chemical Abstracts Service, Columbus, OH,Accession No. 112:35748, RN124612-21-1 & Arch. Pharm. (Weinheim, Ger.), 1989, 322(9), 557-560.
Senga, K., et al., “Synthesis and enzymic activity of various substituted pyrazolo[1 5-a]-1,3,5-triazines as adenosine cyclic 3',5'-phosphate phosphodiesterase inhibitors,”J. Med. Chem.,1982, 25, 243-249.
Springer, et al.,J. Med. Chem.,1976, 19(2), 291-296.
Strohmeyer, T.W., et al., “New synthesis of 2,4-dialkyl . . . ,”J. Het. Chem.,1985, 22(7), 7-10.
J. Het. Chem.,1985, 22, 610.
Arató, M., et al., “Elevated CSF CRF in suicide victims,”Biol. Psychiatry,1989, 25, 355-359.
Armarego, W.L.F., Purification of Laboratory Chemicals, 3rdEd.Pergamon Press, NY,1988.
Banki, C.M., et al., “CSF corticotrophin-releasing factor-like immunoreactivity in depression and schizophrenia,”Am. J. Psychiatry,1987, 144(7), 873-877.
Battaglia, G., et al., “Characterization of corticotropin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system,”Synapse,1987, 1, 572-581.
Berridge, C.W., et al., “A corticotrophin-releasing factor antagonist reverses the stress-induced changes of exploratory behavior in mice,”Horm. And Behav.,1987, 21, 393-401.
Berridge, C.W., et al., “Corticotropin-releasing factor elicits naloxone sensitive stress-like alterations in exploratory behavior in mice,”Regulator Peptides,1986, 16, 83-93.
Blalock, J.E., “A molecular basis for bidirectional communication between the immune and neuroendocrine sysems,”Physiological Reviews,1989, 69(1), 1-32.
Britton, D.R., et al., “Intraventricular corticotrophin-releasing factor enhances behavioral effects of novelty,”Life Sci.,1982, 31, 363-367.
Britton, K.T., et al., “Corticotropin releasing factor and amphetamine exaggerate partial agonist properties of benzodiazepine antagonist Ro 15-1788 in the conflict test,”Psychopharmacology,1988, 94, 306-311.
Britton, K.T., et al., “Chlordiazepoxide attenuates response suppression induced by corticotrophin-releasing factor in the conflict test,”Psychopharmacology,1985, 86, 170-174.
DeSouza, E.B., “CRH defects in alzheimer's and other neurologic diseases,”Hosp. Practice,1988, 23, 59-71.
DeSouza, E.B., “Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution,”J. Neurosci.,1987, 7(1), 88-100.
DeSouza, E.B., et al., “Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study,”J. Neurosci.,1985, 5(12), 3189-3203.
Dunn, A.J., et al., “Physiological and behavioral responses to corticotrophin-releasing factor administration: is CRF a mediator of anxiety or stress responses?, ”Brain Res. Rev.,1990, 15, 71-100.
France, R.D., et al., “CSF corticotrophin-releasing factor-like immunoactivity in chronic pain patients with and without major depression,”Biol. Psychiatry,1988, 23, 86-88.
Gold, P.W., et al., “Psychiatric implications of basic and clinical studies with corticotrophin-releasing factor,”Am. J. Psychiatry,1984, 141(5), 619-627.
Gold, P.W., et al., “Responses to corticotrophin-releasing hormone in the hypercortisolism of depression and cushing's disease,”New Eng. J. Med.,1986, 314, 1329-1335.
Grigoriadis, D.E., et al., “Effects of chronic antidepressant and benzodiazepine treatment on corticotrophin-releasing-factor receptors in rat brain and pituitary,”Neuropsychopharmacology,1989, 2(1), 53-60.
Holsboer, F., et al., “Acth and multisteroid responses to corticotrophin-releasing factor in depressive illness: relationship to multisteroid responses after acth stimulation and dexamethasone suppression,”Psychoneuroendocrinology,1984, 9(2), 147-160.
Koob, G.F., “Stress, corticotrophin-releasing factor, and behavior,”Persp. Behav. Med.,1985, 2, 39-52.
Lancelot, J.-C., et al., “Pyrazolo[1,5d]triazines-1,2,4. I. Dérivépyrazoliques,”J. Het. Chem.,1981, 1319-1324.
Morley, J.E., “Minireview neuropeptides: conductors of the immune orchestra,”Life Sci.,1987, 41, 527-544.
Lee, J.J., et al., “Synthesis of aryl ω-(1-methyl-5-imidazolyl and 1H-5-tetrazolyl)alkyl ketones [1],”J. Het. Chem.,1998, 35, 81-87.
Munson, et al., “Ligand: A versatile computerized approach for characterization of ligand-binding systems,”Anal. Biochem.,1980, 107, 220-239.
Nemeroff, C.B., et al., “Reduced corticotrophin releasing factor binding sites in the frontal cortex of suicide victims,”Arch. Gen. Psychiatry,
Gilligan Paul J.
Wilde Richard G.
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Makujina Shah R.
Woodcock & Washburn LLP
LandOfFree
Pyrazolotriazines as CRF antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolotriazines as CRF antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolotriazines as CRF antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3456049